Economic comparison of oral triptans for management of acute migraine: implications for managed care.

Author: GoldfarbScott D, ReederC E, SteadmanSharm

Paper Details 
Original Abstract of the Article :
Sound, informed decision making regarding which drugs to include on a formulary should be based on the best available evidence of their clinical efficacy and incidence of adverse events. Comparative drug costs and clinical effectiveness should also be considered during the formulary development proc...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/11859908

データ提供:米国国立医学図書館(NLM)

The Economic Value of Oral Triptans for Migraine Treatment

The quest for effective and cost-effective migraine treatments is a challenging one. This study delves into the [economic comparison of oral triptans] for migraine management, aiming to provide valuable insights for healthcare decision-makers. The authors conducted a [meta-analysis of multiple clinical trials] to assess the [efficacy and adverse events] of different triptans. They found that [almotriptan] offers the greatest economic value due to its [comparable efficacy, favorable tolerability, and cost-effectiveness]. These findings have significant implications for [formulary development and patient care], as they can guide decisions about which medications to prioritize for migraine treatment.

Balancing Effectiveness and Cost in Migraine Treatment

Finding the right balance between [efficacy and cost] is a constant challenge in healthcare. This research demonstrates that [almotriptan] stands out as a [cost-effective and efficacious option] for migraine management. This finding is especially important in the context of [managed care], where budget constraints often play a crucial role in treatment decisions.

A Desert Oasis for Migraine Sufferers

Navigating the desert of migraine pain can be a daunting experience. This research offers a glimmer of hope by identifying [almotriptan] as a potentially [effective and affordable treatment option]. This finding can help alleviate the financial burden of migraine treatment, enabling patients to access the care they need without having to navigate the treacherous dunes of high healthcare costs.

Dr. Camel's Conclusion

This study underscores the importance of considering both [efficacy and economic value] when evaluating treatment options for migraine. By identifying almotriptan as a cost-effective and efficacious option, this research provides a valuable tool for healthcare decision-makers, enabling them to navigate the desert of migraine treatment with greater efficiency and effectiveness.

Date :
  1. Date Completed 2002-03-14
  2. Date Revised 2010-11-18
Further Info :

Pubmed ID

11859908

DOI: Digital Object Identifier

365

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.